title: Optimizing the use of aspirin for cardiovascular prevention.
abstract: This article describes the mechanism of action, pharmacokinetics, and pharmacodynamics of aspirin at doses used for cardiovascular prevention and provides specific management recommendations for optimal use in clinical practice. The paper highlights practical aspects related to antiplatelet therapy, including the optimal dose of aspirin, concomitant treatment with other NSAIDs, and strategies for the prevention of gastrointestinal toxicity. Specifically, we revise the benefits and hazards in different clinical settings to help the clinician in the decision-making process for individuals who have different risks for cardiovascular and gastrointestinal bleeding events.
authors.affiliation: Heart Rhythm Management Center, Cardiovascular Division, Cardiovascular Center, Free University of Brussels (UZ Brussels) VUB, Laarbeeklaan 101, Brussels, Belgium. rbcasado@gmail.com
authors.forename: Rubén
authors.initials: R
authors.lastname: Casado-Arroyo
authors.forename: Carlos
authors.initials: C
authors.lastname: Sostres
authors.forename: Angel
authors.initials: A
authors.lastname: Lanas
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin